文献速递慢阻肺肺栓塞与肺血管病

COMPERA注册研究:慢阻肺合并肺动脉高压的预后分析

Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).
PubMed 文献 · Chest · 2021-02-11

基于COMPERA前瞻性注册研究,比较中重度肺动脉高压(PH)合并慢阻肺患者与特发性肺动脉高压(IPAH)患者的特征与结局。男性、低6分钟步行距离和高肺血管阻力是预后不良因素,部分重度PH患者可能从PH治疗中获益。

要点

  • 男性、低6分钟步行距离和高肺血管阻力提示预后不良。
  • 重度PH患者治疗后6分钟步行距离改善≥30米或WHO功能分级改善与更好结局相关。

核心结论

  • 慢阻肺合并PH患者功能受损更重且预后差于IPAH患者。
  • 男性、低6分钟步行距离和高肺血管阻力是慢阻肺合并PH患者死亡预测因素。
  • 部分重度PH的慢阻肺患者可能从PH治疗中获益,需随机对照研究验证。

研究设计与样本

  • COMPERA前瞻性注册研究,纳入新发中重度PH合并慢阻肺患者(中度n=68,重度n=307)及IPAH患者(n=489),均接受PH药物治疗。

主要发现

  • 慢阻肺合并PH患者年龄更大、以男性为主,主要使用磷酸二酯酶-5抑制剂。
  • 尽管血流动力学损害相似,慢阻肺合并PH患者6分钟步行距离更差且WHO功能分级更晚期。
  • 重度PH合并慢阻肺患者中,治疗后6分钟步行距离改善≥30米或WHO功能分级改善与更好结局相关。

关键数值与推荐

  • 中重度PH定义依据第六届世界肺动脉高压研讨会标准。
  • 慢阻肺合并PH患者1、3、5年无移植生存率分别为86%、55%、38%。
  • IPAH患者1、3、5年无移植生存率分别为94%、75%、55%。
  • 6分钟步行距离改善≥30米或WHO功能分级改善与更好结局相关。

临床怎么用

  • 对慢阻肺合并PH患者应评估男性、6分钟步行距离和肺血管阻力以识别高危。
  • 重度PH患者接受PH药物治疗后若6分钟步行距离改善≥30米或WHO功能分级改善提示预后更好。
  • PH治疗在慢阻肺合并重度PH中的获益尚需随机对照研究证实。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pulmonary hypertension (PH) in COPD is a poorly investigated clinical condition. RESEARCH QUESTION: Which factors determine the outcome of PH in COPD? STUDY DESIGN AND METHODS: We analyzed the characteristics and outcome of patients enrolled in the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) with moderate or severe PH in COPD as defined during the 6th PH World Symposium who received medical therapy for PH and compared them with patients with idiopathic pulmonary arterial hypertension (IPAH). RESULTS: The population included incident patients with moderate PH in COPD (n = 68), with severe PH in COPD (n = 307), and with IPAH (n = 489). Patients with PH in COPD were older, predominantly male, and treated mainly with phosphodiesterase-5 inhibitors. Despite similar hemodynamic impairment, patients with PH in COPD achieved a worse 6-min walking distance (6MWD) and showed a more advanced World Health Organization functional class (WHO FC). Transplant-free survival rates at 1, 3, and 5 years were higher in the IPAH group than in the PH in COPD group (IPAH: 94%, 75%, and 55% vs PH in COPD: 86%, 55%, and 38%; P = .004). Risk factors for poor outcomes in PH in COPD were male sex, low 6MWD, and high pulmonary vascular resistance (PVR). In patients with severe PH in COPD, improvements in 6MWD by ≥ 30 m or improvements in WHO FC after initiation of medical therapy were associated with better outcomes. INTERPRETATION: Patients with PH in COPD were functionally more impaired and had a poorer outcome than patients with IPAH. Predictors of death in the PH in COPD group were sex, 6MWD, and PVR. Our data raise the hypothesis that some patients with severe PH in COPD may benefit from PH treatment. Randomized controlled studies are necessary to explore this hypothesis further. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01347216; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Vizza CD, Hoeper MM, Huscher D, et al. Pulmonary Hypertension in Patients With COPD: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Chest. 2021. PMID: 33581097. doi:10.1016/j.chest.2021.02.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。